William Dull Email & Phone Number

Atlanta, Georgia, Us

BiotechExec empowers life science companies to bring groundbreaking, life-saving products to market. We employ a fractional CXO model, forge strategic partnerships, facilitate fundraising, provide operational support, and occupy key advisory board roles, all dedicated to driving our clients' success.• Member of the Executive team leading operations, business development, marketing, strategic planning and channel & partner strategies.• Doubled revenue growth in 2023, grew 3X number of clients and increased margins to 60% by revamping a go-to-market strategy, marketing focus and process improvement activities.• Collaborated with state BIO associations, venture capital/private equity firms, and university technology transfer offices to pinpoint potential clients for incubation and scaling.• Developed the PrecisionMatch process designed to identify and hire the precise candidate for clients. • Provide C-suite advisory & consultative services and strategic business solutions to clients including development of business planning & commercial assessment, growth strategies, fund raising activities, FP&A, regulatory, IP and negotiating licensing agreements for multiple life-science companies.

New York, Ny, Us

InnoMed Infertility Division is a female founded women's health company bringing innovation to the field of infertility. Our goal is to create a new standard of care by researching, developing and commercializing novel medical devices and reproductive methodologies for the infertility space, where there has been a lack of innovation for decades. We are focusing on advancing infertility treatments that optimize outcomes, minimize trauma and discomfort for women seeking infertility options.

Boston, Massachusetts, Us

• Founding executive team member of a new healthcare company (FemTech) dedicated to diagnosing, treating, and improving women's pelvic floor disorders.• Oversaw P&L, commercial, manufacturing, finance, and business operations.• Developed transformational products for value-based care using innovative sensor technologies and a digital health app, setting a new standard in women’s health.• Created and launched Go-To-Market Strategy for Gen 1 product, including HCP and consumer campaigns executed by sales, marketing, operations, access, analytics, and patient hub teams.• Secured Series A & B funding, negotiated a Worldwide IP exclusive license agreement, managed tech-transfer, product and app integration, and led cross-functional R&D for next-gen products.• Built organizational blueprint covering Sales & Marketing, HR, Medical Affairs, Facilities, Manufacturing, Supply Chain, IP, Finance, Market Access, Patient Engagement, Quality, IT, Reimbursement, Compliance, Regulatory, Product Development, and Patient Services/Hub.• Developed and implemented a compliance & ethics program including training, education, monitoring, auditing, transparency, and communications.Achievements:o Created a scalable commercial model with optimized sales & marketing, channel and payer strategies, DTC campaigns, e-commerce, digital promotion, and new distribution channels including telemedicine, driving revenue and user growth.o $70M in venture-backed and debt funding/financing. o Managed daily operations, systems, and process improvements.o Conducted a successful PoC clinical study with positive outcomes and developed life cycle management strategies to expand the product label.o Led R&D with a medical device partner for next-gen products and ensured adequate supply chain forecasting with the current manufacturer.

• Developed and headed the global rare disease go-to-market commercialization strategy and execution for the US, EMEA, and International regions to successfully launch a portfolio of therapeutics (lomitapide and metreleptin) to maximize the market revenue/potential. • Led high-performing global teams consisting of market research, HCP/Patient marketing, patient advocacy, psales operations and training, analytics, and promotional review.• Formulated global forecasting, access and pricing strategies, and as a key member of the Lifecycle Management Team, established regulatory priorities and explored new formulations and label expansions.• Notable achievements while in the position included:o Orchestrated global brand strategies which accelerated launches in multiple counties, leading to $250M in global sales in 2015.o Successfully integrated and transitioned metreleptin (purchased from AZ), leading to $26M in first-year US sales, while collaborating with Regulatory teams preparing to register the compound in additional countries. o Cultivated a global cross-functional team of Medical, Marketing, Regulatory, and Access with experience across all geographical regions tasked with successfully commercializing therapies and protected the business from new market entrants.o Gained commercial access and reimbursement in multiple countries by creating and delivering a value proposition, messaging, and dossiers in concert with the new EMEA team, patient engagement,

• Built a new department from the ground-up with a focus on all patient-related activities that included teams of Nurses (PEM), Registered Dietitians, and Patient Marketing for our rare disease platform. • Led marketing groups in the design and execution of all patient models, adherence tactics, resources, and interventions to enhance the patient experience and implement a focus on a commitment to treating their specific disease. • Worked in collaboration with VP Patient Services on Specialty Pharmacy (SP) strategies and tactics to optimize patient care through an in-house Case Management Group. • Notable achievements while in the position included:o Increased PEM patient on-boarding to 80% and RD consults to 90%, resulting in higher patient conversion and adherence rates. o Decreased patient-elected drops by 20% while increasing long-term compliance to 86%.o Served as a lead member of the Operational Excellence project team that developed the organization's PlayBook, resulting in improved performance consistency and process enhancements across the commercial group by leveraging a new Matrix model framework.

• Recruited, hired and managed a group of high-performing sales teams to prepare the company to launch novel therapeutics in the rare/orphan space and to drive the achievement of defined US sales performance targets. • Partnered with US Marketing, Medical Affairs, and Commercial Operations to develop and execute the launch plan, KOL management, sales meetings, performance analytics, KPIs, and training materials. • Worked in collaboration with Managed Care teams to ensure patient and HCP access/coverage to the product. • Notable achievements while in the position included:o Recognized as a “President Cup” winner in 2013.o Ignited sales team to achieve a 2X revenue launch forecast of year 1 sales of $40M.o Delivered 90%+ in market share over the competition and a 60% formulary approval rate with managed care.

• Brought on board specifically to establish and operationalize the Sales department including Sales Operations, Analytics and Business Intelligence, Human Resources, and Sales Training of a newly formed neurology company.• Partnered and oversaw the outsourcing organization to develop and execute the launch readiness sales plan.• Teamed with head of sales, assembled and hired an organization comprised of 9 Regional Business Sales Directors and 110 Field Specialty Representatives. • Added valued input while supporting the identification of SP distribution strategies and the HUB support systems, payer/pricing research and value proposition.• Notable achievements while in the position included:o Developed the overall commercial strategy and launch of the Alliance for HOH, a coalition of KOL physicians and patient advocacy groups that increased disease awareness and treatment options for a rare disorder.

Oklahoma City, Ok, Us

• Member of the Executive Management Team, led P&L, finance, contracting, sales and marketing, project and program management, business and corporate development activities, and all client-related services in the Protein Contract Manufacturing space.• Worked in collaboration with contracted companies to optimize product development to maximize market potential. • Evaluated protein expression platforms and scientific technologies aimed at expanding the menu of services.• Focused on capital efficiencies, cash flow, balance sheet, OPEX and resource allocation to ensure corporate growth. • Notable achievements while in the position included:o Maintained full responsibility for profit & loss, devised and implemented the business development strategy that grew revenue from $3M to $7M in 2010 and successfully closed new business producing revenue of >$15M in 2011.o Successfully negotiated a $22.5M private equity (PE) raise in 2010 with the CEO.o Led cross-functional teams to scale business across multiple disciplines through process improvements that resulted in more customers and higher customer satisfaction o Applied Lean Six Sigma principles to improve operational excellence, resulting in increased company efficiencies and process improvements across all facets of the organization.